Clinical trial
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
NCT00126568 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00126568 |
|---|---|
| Title | Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer |
| Official title | Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer |
| Intervention type | Drug |
| Interventions | sorafenib tosylate |
| Enrollment | 20 |
| Start date | Jun 1, 2005 |
| Primary completion | Sep 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | Aug 4, 2005 |
| Last update posted | Jan 19, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: